The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Open accessAbstract
Hematopoiesis, the process by which the hematopoietic stem cells and progenitors differentiate into blood cells of various lineages, involves complex interactions of transcription factors that modulate the expression of downstream genes and mediate proliferation and differentiation signals. Despite the many controls that regulate hematopoiesis, mutations in the regulatory genes capable of promoting leukemogenesis may occur. The FLT3 gene encodes a tyrosine kinase receptor that plays a key role in controlling survival, proliferation and differentiation of hematopoietic cells. Mutations in this gene are critical in causing a deregulation of the delicate balance between cell proliferation and differentiation. In this review, we provide an update on the structure, synthesis and activation of the FLT3 receptor and the subsequent activation of multiple downstream signaling pathways. We also review activating FLT3 mutations that are frequently identified in acute myeloid leukemia, cause activation of more complex downstream signaling pathways and promote leukemogenesis. Finally, FLT3 has emerged as an important target for molecular therapy. We, therefore, report on some recent therapies directed against it.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1752 · Cited by 1,551
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,162
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,150
Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C. M., Serve, H., Büchner, T., et al. (2002) · Blood · doi:10.1182/blood.v100.1.59 · Cited by 973
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Blocking Oncogenic Ras Signaling for Cancer Therapy
Adjei, A. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1062 · Cited by 831
c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities
Lyman, S. D., & Jacobsen, S. E. W. (1998) · Blood · doi:10.1182/blood.v91.4.1101 · Cited by 696
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Whitman, S. P., Archer, K. J., Lin, F., Baldus, C. D., Becknell, B., Carlson, B. D., Carroll, A. J., Mrózek, K., Vardiman, J., George, S. L., et al. (2001) · PubMed · Cited by 633
Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Müller, C., Grüning, W., Kratz-Albers, K., Serve, S., Steur, C., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3907 · Cited by 606
Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., & Naoe, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203354 · Cited by 579
Lyman, S. D., James, L., Bos, T. V., de Vries, P., Brasel, K., Gliniak, B., Hollingsworth, L. T., Picha, K. S., McKenna, H. J., Splett, R. R., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90325-k · Cited by 527
Fischer, T., Stone, R. M., DeAngelo, D. J., Galinsky, I., Estey, E., Lanza, C., Fox, E., Ehninger, G., Feldman, E. J., Schiller, G. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9678 · Cited by 504
The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain
Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., & Saxena, K. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00505-7 · Cited by 499
FLT3: ITDoes matter in leukemia
Levis, M., & Small, D. (2003) · Leukemia · doi:10.1038/sj.leu.2403099 · Cited by 495
Nosaka, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4754 · Cited by 491
Knapper, S., Burnett, A. K., Littlewood, T., Kell, W. J., Agrawal, S., Chopra, R., Clark, R., Levis, M. J., & Small, D. (2006) · Blood · doi:10.1182/blood-2006-04-015560 · Cited by 413
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301796 · Cited by 398
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Xu, Q., Simpson, S.-E., Scialla, T. J., Bagg, A., & Carroll, M. (2003) · Blood · doi:10.1182/blood-2002-11-3429 · Cited by 394
Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia
Abu‐Duhier, F. M., Goodeve, A. C., Wilson, G. A., Care, R. S., Peake, I. R., & Reilly, J. T. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02850.x · Cited by 388
FLT3 as a therapeutic target in AML: still challenging after all these years
Kindler, T., Lipka, D. B., & Fischer, T. (2010) · Blood · doi:10.1182/blood-2010-04-261867 · Cited by 384
Ravandi, F., Cortes, J. E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M. Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4888 · Cited by 356
Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells
Rosnet, O., Schiff, C., Pebusque, M., Marchetto, S., Tonnelle, C., Toiron, Y., Birg, F., & Birnbaum, D. (1993) · Blood · doi:10.1182/blood.v82.4.1110.1110 · Cited by 349
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
Zhang, W., Konopleva, M., Shi, Y.-X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintás-Cardama, A., Small, D., Cortes, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm328 · Cited by 338
Lyman, S., James, L., Johnson, L., Brasel, K., de Vries, P., Escobar, S., Downey, H., Splett, R., Beckmann, M., & McKenna, H. (1994) · Blood · doi:10.1182/blood.v83.10.2795.2795 · Cited by 298
The Molecular Basis of Leukemia
Gilliland, D. G., Jordan, C. T., & Felix, C. A. (2004) · Hematology · doi:10.1182/asheducation-2004.1.80 · Cited by 273
Choudhary, C., Schwäble, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W. E., Müller-Tidow, C., & Serve, H. (2005) · Blood · doi:10.1182/blood-2004-07-2942 · Cited by 263
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Sato, T., Yang, X., Knapper, S., White, P., Smith, B. D., Galkin, S., Small, D., Burnett, A., & Levis, M. (2011) · Blood · doi:10.1182/blood-2010-01-266742 · Cited by 261
Martelli, A. M., Evangelisti, C., Chiarini, F., & McCubrey, J. A. (2010) · Oncotarget · doi:10.18632/oncotarget.114 · Cited by 248
Rosnet, O., Bühring, H. ‐., Marchetto, S., Rappold, I., Lavagna, C., Sainty, D., Arnoulet, C., Chabannon, C., Kanz, L., Hannum, C. H., et al. (1996) · PubMed · Cited by 245
Takahashi, S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-13 · Cited by 241
Kim, K.-T., Baird, K., Ahn, J.-Y., Meltzer, P., Lilly, M., Levis, M., & Small, D. (2005) · Blood · doi:10.1182/blood-2004-05-2006 · Cited by 234
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1485 · Cited by 233
A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer
Yang, J.-Y., & Hung, M.-C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0124 · Cited by 228
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
Zheng, R., Levis, M., Piloto, O., Brown, P., Baldwin, B. R., Gorin, N. C., Beran, M., Zhu, Z., Ludwig, D., Hicklin, D., et al. (2004) · Blood · doi:10.1182/blood-2003-06-1969 · Cited by 205
Molecular genetics of human leukemias: New insights into therapy
Gilliland, D. G. (2002) · Seminars in Hematology · doi:10.1053/shem.2002.36921 · Cited by 203
Spiekermann, K., Bagrintseva, K., Schwab, R., Schmieja, K., & Hiddemann, W. (2003) · PubMed · Cited by 184
Kikushige, Y., Yoshimoto, G., Miyamoto, T., Iino, T., Mori, Y., Iwasaki, H., Niiro, H., Takenaka, K., Nagafuji, K., Harada, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7358 · Cited by 181
Zhang, W., Konopleva, M., Ruvolo, V. R., McQueen, T., Evans, R. L., Bornmann, W. G., McCubrey, J., Cortes, J., & Andreeff, M. (2008) · Leukemia · doi:10.1038/sj.leu.2405098 · Cited by 170
Zhang, Y., Gan, B., Liu, D., & Paik, J.-H. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.15954 · Cited by 167
Zheng, R., Friedman, A. D., Levis, M. J., Li, L., Weir, E. G., & Small, D. (2003) · Blood · doi:10.1182/blood-2003-06-1978 · Cited by 162
Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene
Rosnet, O., Matteï, M.-G., Marchetto, S., & Birnbaum, D. (1991) · Genomics · doi:10.1016/0888-7543(91)90270-o · Cited by 161
D. Kottaridis, P., Gale, R. E., & Linch, D. C. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04500.x · Cited by 158
Deregulation of Signaling Pathways in Acute Myeloid Leukemia
Scholl, C., Gilliland, D. G., & Fröhling, S. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.004 · Cited by 149
Fenski, Flesch, Serve, Mizuki, Oelmann, Kratz‐Albers, Kienast, Leo, Schwartz, Berdel, et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01831.x · Cited by 146
Reindl, C., Bagrintseva, K., Vempati, S., Schnittger, S., Ellwart, J. W., Wenig, K., Hopfner, K., Hiddemann, W., & Spiekermann, K. (2006) · Blood · doi:10.1182/blood-2005-06-2596 · Cited by 143
Yonemura, Y., Ku, H. T., Lyman, S. D., & Ogawa, M. (1997) · Blood · doi:10.1182/blood.v89.6.1915 · Cited by 142
Breitenbuecher, F., Schnittger, S., Grundler, R., Markova, B., Carius, B., Brecht, A., Duyster, J., Haferlach, T., Huber, C., & Fischer, T. H. (2008) · Blood · doi:10.1182/blood-2007-11-125476 · Cited by 138
Scheijen, B., Ngo, H. T., Kang, H. K., & Griffin, J. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207456 · Cited by 128
Zhang, S., & Broxmeyer, H. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3662 · Cited by 117
Zhang, S., Mantel, C., & Broxmeyer, H. E. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.3.372 · Cited by 114
Bagrintseva, K., Geisenhof, S., Kern, R., Eichenlaub, S., Reindl, C., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2004) · Blood · doi:10.1182/blood-2004-06-2459 · Cited by 112
Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction
Tickenbrock, L., Schwäble, J., Wiedehage, M., Steffen, B., Sargin, B., Choudhary, C., Brandts, C., Berdel, W. E., Müller‐Tidow, C., & Serve, H. L. (2005) · Blood · doi:10.1182/blood-2004-07-2924 · Cited by 112
Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.
Meierhoff, G., Dehmel, U., Gruss, H. J., Rosnet, O., Birnbaum, D., Quentmeier, H., Dirks, W. G., & Drexler, H. G. (1995) · PubMed · Cited by 110
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia
Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00080-6 · Cited by 110
Agnès, F., Shamoon, B., Dina, C., Rosnet, O., Birnbaum, D., & Galibert, F. (1994) · Gene · doi:10.1016/0378-1119(94)90021-3 · Cited by 108
Bruserud, Ø., Hovland, R., Wergeland, L., Huang, T., & Gjertsen, B. T. (2003) · PubMed · Cited by 102
Drug resistance in mutant FLT3-positive AML
Weisberg, E., Sattler, M., Ray, A., & Griffin, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.273 · Cited by 93
Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1
Kim, K., Levis, M. J., & Small, D. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06225.x · Cited by 93
Maroc, N., Rottapel, R. K., Rosnet, O., Marchetto, S., Lavezzi, C., Mannoni, P., Birnbaum, D., & Dubreuil, P. C. (1993) · PubMed · Cited by 92
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
Jiang, J., Paez, J. G., Lee, J. C., Bo, R., Stone, R. M., DeAngelo, D. J., Galinsky, I. A., Wolpin, B. M., Jonasova, A. T., Herman, P. K., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0712 · Cited by 90
Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside
Shabbir, M., & Stuart, R. K. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003598862 · Cited by 89
Targeting mTOR for the treatment of AML. New agents and new directions
Altman, J. K., Sassano, A., & Platanias, L. C. (2011) · Oncotarget · doi:10.18632/oncotarget.290 · Cited by 87
Genomic structure of human FLT3: implications for mutational analysis
Abu‐Duhier, F. M., Goodeve, A. C., Wilson, G. A., Care, R. S., Peake, I. R., & Reilly, J. T. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02821.x · Cited by 84
FLT3 inhibitors in the treatment of acute myeloid leukemia
Pemmaraju, N., Kantarjian, H. M., Ravandi, F., & Cortes, J. E. (2011) · Cancer · doi:10.1002/cncr.25908 · Cited by 84
Bagrintseva, K., Schwab, R., Kohl, T. M., Schnittger, S., Eichenlaub, S., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2003) · Blood · doi:10.1182/blood-2003-05-1653 · Cited by 77
Flt3high and Flt3low CD34+Progenitor Cells Isolated From Human Bone Marrow Are Functionally Distinct
Götze, K. S. S., Ramírez, M. R., Tabor, K., Small, D., Matthews, W., & Civin, C. I. (1998) · Blood · doi:10.1182/blood.v91.6.1947 · Cited by 75
SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor
Marchetto, S., Fournier, E., Beslu, N., Aurran, T., Dubreuil, P. C., Borg, J., Birnbaum, D., & Rosnet, O. (1999) · Leukemia · doi:10.1038/sj.leu.2401527 · Cited by 75
FLT3/ITD AML and the law of unintended consequences
Levis, M. J. (2011) · Blood · doi:10.1182/blood-2011-03-340273 · Cited by 73
FLT-3: a new focus in the understanding of acute leukemia
Marković, A. K., MacKenzie, K. L., & Lock, R. B. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.12.005 · Cited by 73
Brown, P. A., & Small, D. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.08.030 · Cited by 62
Irons, R., & Stillman, W. S. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.961041239 · Cited by 59
FLT3 inhibitors: a story of the old and the new
Fathi, A. T., & Levis, M. J. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283439a03 · Cited by 59
Au, W. Y., Fung, A. T., Chim, C. S., Lie, A. K. W., Liang, R. H. S., Ma, E. S. K., Chan, C. H., Wong, K. F., & Kwong, Y. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04935.x · Cited by 58
Novel protein kinases and molecular mechanisms of autoinhibition
Cheetham, G. M. T. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.10.011 · Cited by 58
Chung, K. Y., Morrone, G., Schuringa, J. J., Wong, B. Y., Dorn, D. C., & Moore, M. A. S. (2004) · Blood · doi:10.1182/blood-2003-12-4445 · Cited by 54
Stölzel, F., Steudel, C., Oelschlägel, U., Mohr, B., Koch, S., Ehninger, G., & Thiede, C. (2010) · Annals of Hematology · doi:10.1007/s00277-009-0889-1 · Cited by 46
FLT3/ITD Mutation Signaling Includes Suppression of SHP-1
Chen, P., Levis, M. J., Brown, P. A., Kim, K.-T., Allebach, J., & Small, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411974200 · Cited by 44
Tiesmeier, J., Müller‐Tidow, C., Westermann, A., Czwalinna, A., Hoffmann, M., Krauter, J., Heil, G., Ganser, A., Serve, H. L., & Verbeek, W. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.02.009 · Cited by 42
Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia
Zwaan, C. M., & Kaspers, G. J. L. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05167.x · Cited by 38
Treatment of FLT3-ITD acute myeloid leukemia.
Fathi, A. T., & Chen, Y. (2011) · PubMed Central · Cited by 37
FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3
Jönsson, M. E., Engström, M., & Jönsson, J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.110 · Cited by 36
The Role of Molecular Tests in Acute Myelogenous Leukemia Treatment Decisions
Motyckova, G., & Stone, R. M. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0049-7 · Cited by 34
Sritana, N., & Auewarakul, C. U. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.09.004 · Cited by 19
FLT3 mutations are associated with other molecular lesions in AML
Carnicer, M. J., Nomdedeu, J. F., Lasa, A., Estivill, C., Brunet, S., n, A. A. X., & Sierra, J. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00125-5 · Cited by 18
Cited by
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,075
Click, Z. R., Seddon, A. N., Bae, Y. R., Fisher, J. D., & Ogunniyi, A. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2180 · Cited by 18
Metadata
- Authors
- Grafone, T., Palmisano, M., Nicci, C., & Storti, S.
- Venue
- Oncology Reviews
- Publisher
- Frontiers Media SA
- Published
- 2012-04-17
- Volume
- 6
- Issue
- 1
- Pages
- 8
- ISSN
- 1970-5557 (ISSN-L)
- 1970-5565
- OpenAlex
- W2160140526
- Cited by
- 273
- References
- 90
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.